These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
335 related articles for article (PubMed ID: 7571214)
1. Economic modeling to assess the costs of treatment with finasteride, terazosin, and transurethral resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia. Lowe FC; McDaniel RL; Chmiel JJ; Hillman AL Urology; 1995 Oct; 46(4):477-83. PubMed ID: 7571214 [TBL] [Abstract][Full Text] [Related]
2. An evaluation of the economic costs and patient-related consequences of treatments for benign prostatic hyperplasia. DiSantostefano RL; Biddle AK; Lavelle JP BJU Int; 2006 May; 97(5):1007-16. PubMed ID: 16542339 [TBL] [Abstract][Full Text] [Related]
3. Efficacy of terazosin and finasteride in symptomatic benign prostatic hyperplasia: A comparative study. Anwarul Islam AK; Kashem MA; Shameem IA; Kibria SA Bangladesh Med Res Counc Bull; 2005 Aug; 31(2):54-61. PubMed ID: 16967810 [TBL] [Abstract][Full Text] [Related]
4. Terazosin. A pharmacoeconomic evaluation of its use in benign prostatic hyperplasia. Plosker GL; Goa KL Pharmacoeconomics; 1997 Feb; 11(2):184-97. PubMed ID: 10165827 [TBL] [Abstract][Full Text] [Related]
5. Comparison of percent free prostate-specific antigen levels in men with benign prostatic hyperplasia treated with finasteride, terazosin, or watchful waiting. Keetch DW; Andriole GL; Ratliff TL; Catalona WJ Urology; 1997 Dec; 50(6):901-5. PubMed ID: 9426721 [TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of tamsulosin, doxazosin, and terazosin in the treatment of benign prostatic hyperplasia. Ohsfeldt RL; Kreder KJ; Klein RW; Chrischilles EA J Manag Care Pharm; 2004; 10(5):412-22. PubMed ID: 15369424 [TBL] [Abstract][Full Text] [Related]
7. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. Lepor H; Williford WO; Barry MJ; Brawer MK; Dixon CM; Gormley G; Haakenson C; Machi M; Narayan P; Padley RJ N Engl J Med; 1996 Aug; 335(8):533-9. PubMed ID: 8684407 [TBL] [Abstract][Full Text] [Related]
8. An economic evaluation of doxazosin, finasteride and combination therapy in the treatment of benign prostatic hyperplasia. McDonald H; Hux M; Brisson M; Bernard L; Nickel JC Can J Urol; 2004 Aug; 11(4):2327-40. PubMed ID: 15380054 [TBL] [Abstract][Full Text] [Related]
9. Changes in nocturia from medical treatment of benign prostatic hyperplasia: secondary analysis of the Department of Veterans Affairs Cooperative Study Trial. Johnson TM; Jones K; Williford WO; Kutner MH; Issa MM; Lepor H J Urol; 2003 Jul; 170(1):145-8. PubMed ID: 12796667 [TBL] [Abstract][Full Text] [Related]
10. The American Urological Association symptom score in the evaluation of men with lower urinary tract symptoms: at 2 years of followup, does it work? Kaplan SA; Olsson CA; Te AE J Urol; 1996 Jun; 155(6):1971-4. PubMed ID: 8618299 [TBL] [Abstract][Full Text] [Related]
11. Long-term cost analysis of treatment options for benign prostatic hyperplasia in Norway. Johansen TE; Istad JA Scand J Urol Nephrol; 2007; 41(2):124-31. PubMed ID: 17454951 [TBL] [Abstract][Full Text] [Related]
12. Economic analysis of finasteride: a model-based approach using data from the Proscar Long-Term Efficacy and Safety Study. Albertsen PC; Pellissier JM; Lowe FC; Girman CJ; Roehrborn CG Clin Ther; 1999 Jun; 21(6):1006-24. PubMed ID: 10440624 [TBL] [Abstract][Full Text] [Related]
13. The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. Lepor H; Williford WO; Barry MJ; Haakenson C; Jones K J Urol; 1998 Oct; 160(4):1358-67. PubMed ID: 9751354 [TBL] [Abstract][Full Text] [Related]
14. The impact of 5-alpha-reductase inhibitors on the number of prostatectomies for benign prostatic hyperplasia. Agha AH; Roy JB; Culkin DJ; Lyon K Adv Ther; 1995; 12(6):361-6. PubMed ID: 10163332 [TBL] [Abstract][Full Text] [Related]
15. Prospective randomized comparison of high energy transurethral microwave thermotherapy versus alpha-blocker treatment of patients with benign prostatic hyperplasia. Djavan B; Roehrborn CG; Shariat S; Ghawidel K; Marberger M J Urol; 1999 Jan; 161(1):139-43. PubMed ID: 10037386 [TBL] [Abstract][Full Text] [Related]
16. Terazosin in the treatment of hypertension and symptomatic benign prostatic hyperplasia: a primary care trial. Guthrie R J Fam Pract; 1994 Aug; 39(2):129-33. PubMed ID: 7520053 [TBL] [Abstract][Full Text] [Related]
17. Terazosin vs finasteride for BPH. Zacks M J Fam Pract; 1996 Dec; 43(6):533. PubMed ID: 8969692 [No Abstract] [Full Text] [Related]
18. Benign prostatic hyperplasia: diagnosis and treatment. Agency for Health Care Policy and Research. McConnell JD; Barry MJ; Bruskewitz RC Clin Pract Guidel Quick Ref Guide Clin; 1994 Feb; (8):1-17. PubMed ID: 7507389 [TBL] [Abstract][Full Text] [Related]
19. The impact of medical therapy on surgery for benign prostatic hyperplasia: a study comparing changes in a decade (1992-2002). Vela-Navarrete R; Gonzalez-Enguita C; Garcia-Cardoso JV; Manzarbeitia F; Sarasa-Corral JL; Granizo JJ BJU Int; 2005 Nov; 96(7):1045-8. PubMed ID: 16225526 [TBL] [Abstract][Full Text] [Related]
20. A cost comparison of medical management and transurethral needle ablation for treatment of benign prostatic hyperplasia during a 5-year period. Naslund MJ; Carlson AM; Williams MJ J Urol; 2005 Jun; 173(6):2090-3; discussion 2093. PubMed ID: 15879849 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]